OpenNeedle Ask your own

Question explored with the scientific record

How is the pneumonia vaccine for people about 72 years old but relatively good health

Nov 17, 2026 · 6 sources used · OpenNeedle synthesis
The short version: for a healthy 72-year-old, the pneumonia vaccine is a modest bet, not a slam dunk. It cuts one specific kind of pneumonia, not pneumonia in general, and the best evidence is in people sicker than you.

The strongest data come from a large randomized trial in adults 65 and older, the kind of trial that can actually prove cause and effect. It found the conjugate vaccine (PCV13) cut vaccine-type pneumonia by about 46% and invasive pneumococcal disease by about 75% [2]. But it did not significantly reduce pneumonia from all causes [2][4]. So the benefit is real but narrow: it protects against the strains in the shot, not the many other bugs that cause pneumonia.

OutcomeWhat the trial showed
Vaccine-type pneumonia~46% fewer cases [2]
Invasive pneumococcal disease~75% fewer cases [2]
Pneumonia from any causeNo significant reduction [2][4]
All-cause death (older polysaccharide shot)No significant reduction [3]

The older polysaccharide vaccine (PPSV23) is weaker. A 2024 meta-analysis found it did not significantly reduce all-cause death, though it did cut pneumonia-related death [3]. One observational study found no clear benefit in people without HIV [1]. And immune response does blunt with age, so a 72-year-old mounts a weaker response than a 50-year-old [5][6].

On safety, the trials reported more local reactions but no serious vaccine-related events [2][4]. That is short-term data. This retrieval contains no long-term safety study, and absence of evidence is not evidence of safety.

My call: a reasonable, low-risk choice for a healthy 72-year-old, with a modest and narrow benefit, not a must. Confidence: moderate.

Keep digging

Sources used 6

  1. Impact of Pneumococcal Vaccination on the Incidence of Pneumonia by HIV Infection Status among Patients Enrolled in the Veterans Aging Cohort 5‐Site Study Clinical Infectious Diseases (2008) Thin

    A prospective Veterans Affairs cohort study shows that pneumococcal vaccination (PPV) reduces pneumonia risk among HIV-infected veterans, while showing no clear benefit in HIV-uninfected veterans, after adjusting for multiple comorbidities and HIV-related factors.

    DOI: 10.1086/529201
  2. Is 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Combined With 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) Superior to PPSV23 Alone for Reducing Incidence or Severity of Pneumonia in Older Adults? A Clin-IQ Journal of Patient-Centered Research and Reviews (2016) narrative review Strong

    PCV13 reduced vaccine-type pneumococcal CAP and invasive pneumococcal disease in older adults and had no serious adverse events, but did not significantly reduce all-cause CAP or non-vaccine-type CAP; the review concludes PCV13 is effective for vaccine-type disease.

    DOI: 10.17294/2330-0698.1214
  3. Mortality reduction with 23-valent pneumococcal polysaccharide vaccine: a systematic review and meta-analysis Pneumonia (2024) Thin

    This systematic review and meta-analysis evaluated the effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPV23) in reducing all-cause and pneumonia-related mortality among adults, finding no significant reduction in all-cause mortality but a significant reducti…

    DOI: 10.1186/s41479-024-00149-5
  4. How effective is 13-valent pneumococcal conjugate vaccine (PCV13) combined with 23-valent pneumococcal polysaccharide vaccine (PPSV23)? UCC Student Medical Journal (2024) systematic review Strong

    This systematic review of 10 studies concluded that PCV13 combined with PPSV23 produces a greater immune response than PPSV23 alone in adults aged 50 years and older, with no vaccine-related serious adverse events reported, but clinical superiority remains unresolved.

    DOI: 10.33178/smj.2021.1.3
  5. B Cell Immunosenescence Annual Review of Cell and Developmental Biology (2020) Thin

    A comprehensive review of how aging affects B cell development, subsets, antibody production, and vaccine responses, highlighting inflammaging, obesity as a modulator, CMV and microbiome influences, and the emergence of proinflammatory B cell types that diminish humoral immunity…

    DOI: 10.1146/annurev-cellbio-011620-034148
  6. Regulatory T cells and vaccine effectiveness in older adults. Challenges and prospects International Immunopharmacology (2021) Thin

    This minireview synthesizes current knowledge on how regulatory T cells (Tregs) influence vaccine responses in older adults, highlighting aging-associated Treg expansion as a factor in reduced vaccine effectiveness and outlining strategies to modulate Tregs to improve immunogeni…

    DOI: 10.1016/j.intimp.2021.107761

Your question next

What do you want to know?

No question is too uncomfortable for the evidence. Bring yours.

Ask your question →